And with us now here at Fenway, it is Christopher Lathen, who is the chief clinical access officer

at Dana Farber. Thanks for being here. How are you? It's great. It's always a pleasure to be here

with you guys. It's incredible because you guys do what you do every single day. We come here

and do these two days, and we get to hear some of the stories, but you guys are there every single

day. And so are better able to share with those who are thinking about giving those who have

given the effect that a simple $5, $10, $25 donation can have on those who are fighting cancer.

Yeah. I think it's, you know, I've been blessed to be able to be part of

patients' lives where they go through this journey, right?

And, you know, cancer doesn't care where you came from.

And but it does, what we've seen over the past 20 years is this incredible impact and the

way we've been able to treat cancer, the way we've been able to cure it in some situations.

And it's amazing that every gift, every time somebody calls in and gives, it really, really helps,

not only the research, but then programs like mine where I'm also trying to make sure that,

you know, every community, you know, hope is not restricted to just one community.

Every community should have access to hope.

And so that's what we're trying to do. So really, these gifts help the research, but they also

help us make sure that research impacts individual lives. And I think it's important to note how much

progress has been made. And we were talking about this event has been going on for 23 years.

There used to be things that were death sentences that aren't anymore. That's right. So I treat lung cancer. And so 23 years ago, you know, when I started, actually, I started my fellowship at the Dana Farber. You know, when I started my clinic, we only had a few tools. And, you know, you would hope to be lucky to be able to slow down the cancer a little bit, especially if they saw me as a medical oncologist. But now I have people and sometimes, some folks have been on this show where they had a metastatic lung cancer. We treated them with what was then an experimental drug, which is now a standard drug, Ketruda or, you know, Pemberlizumab. And, you know, that person is seven years out,

not hasn't been. drug, which is now a standard drug, Ketruda or Pemberlizumab. And, you know, that person is

seven years out, hasn't been on any therapy. He comes, he rides his bike in. It's really

amazing. It's so amazing. What's so interesting with you specifically is your focus really on,

...